Abstract
Cyclooxygenase (COX) and lipoxygenase (LO) metabolic pathways are emerging as key regulators of cell proliferation and neo-angiogenesis. COX and LO inhibitors are being investigated as potential anticancer drugs and results from clinical trials seem to be encouraging. In this article we will review evidence of COX-2 and 5-LO involvement in cancer pathobiology, propose a model of integrated control of cell proliferation by these enzymes, and discuss the pharmacologic implications of this model.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Arachidonate 5-Lipoxygenase / physiology*
-
Cell Division
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / therapeutic use
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / physiology*
-
Lipoxygenase Inhibitors / therapeutic use
-
Membrane Proteins
-
Models, Biological
-
Neoplasms / blood supply
-
Neoplasms / drug therapy
-
Neoplasms / enzymology*
-
Neoplasms / etiology
-
Neovascularization, Pathologic
-
Prostaglandin-Endoperoxide Synthases / physiology*
Substances
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Lipoxygenase Inhibitors
-
Membrane Proteins
-
Arachidonate 5-Lipoxygenase
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases